Dasatinib ameliorates thioacetamide-induced liver fibrosis: modulation of miR-378 and miR-17 and their linked Wnt/b-catenin and TGF-b/smads pathways
| dc.Affiliation | October University for modern sciences and Arts (MSA) | |
| dc.contributor.author | Zaafan, Mai A | |
| dc.contributor.author | Abdelhamid, Amr M | |
| dc.date.accessioned | 2021-12-15T07:39:49Z | |
| dc.date.available | 2021-12-15T07:39:49Z | |
| dc.date.issued | 11/12/2021 | |
| dc.description | SJR 2024 0.857 Q2 H-Index 98 | |
| dc.description.abstract | Hepatic stellate cells activation (HSCs) plays a crucial role in the pathogenesis of liver fibrosis. Specific microRNAs have been suggested to affect the activation of HSCs via various signalling pathways including TGF-β/smads and Wnt/β-catenin pathways. Dasatinib is a multitarget inhibitor of many tyrosine kinases has recently studied for its anti-fibrotic effects in a variety of fibrous diseases. This study investigated the role of modulation of miRNA-378 and miRNA-17 in the pathogenesis of liver fibrosis through altering Wnt/β-catenin and TGF-β/smads pathways and evaluated the beneficial effect of the tyrosine kinase inhibitor, dasatinib, in thioacetamide-induced liver fibrosis model in mice. Treatment with dasatinib down-regulated miRNA-17 expression, leading to the restoration of WiF-1 and smad-7 which cause the inhibition of both Wnt/β-catenin and TGF-β/smads signalling. In addition, it upregulated miRNA-378 leading to the decrease of Wnt-10 which contributes to the suppression of activated HSCs. | en_US |
| dc.description.uri | https://www.scimagojr.com/journalsearch.php?q=17605&tip=sid&clean=0 | |
| dc.identifier.citation | Zaafan, M. A., & Abdelhamid, A. M. (2021). Dasatinib ameliorates thioacetamide-induced liver fibrosis: modulation of miR-378 and miR-17 and their linked Wnt/β-catenin and TGF-β/smads pathways. Journal of Enzyme Inhibition and Medicinal Chemistry, 37(1), 118–124. https://doi.org/10.1080/14756366.2021.1995379 | |
| dc.identifier.doi | https://doi.org/10.1080/14756366.2021.1995379 | |
| dc.identifier.other | https://doi.org/10.1080/14756366.2021.1995379 | |
| dc.identifier.uri | http://repository.msa.edu.eg/xmlui/handle/123456789/4797 | |
| dc.language.iso | en_US | en_US |
| dc.publisher | Taylor and Francis | en_US |
| dc.relation.ispartofseries | JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY ;2022;VOL. 37, NO. 1, 118–124 | |
| dc.subject | Dasatinib | en_US |
| dc.subject | liver fibrosis | en_US |
| dc.subject | smad-3 | en_US |
| dc.subject | Wnt-10 | en_US |
| dc.subject | mice | en_US |
| dc.title | Dasatinib ameliorates thioacetamide-induced liver fibrosis: modulation of miR-378 and miR-17 and their linked Wnt/b-catenin and TGF-b/smads pathways | en_US |
| dc.type | Article | en_US |